Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This review takes a sceptical view of the impact of breast cancer studies that have used microarrays to identify predictors of clinical outcome. In addition to discussing general pitfalls of microarray experiments, we also critically review the key breast cancer studies to highlight methodological problems in cohort selection, statistical analysis, validation of results and reporting of raw data. We conclude that the optimum use of microarrays in clinical studies requires further optimisation and standardisation of methodology and reporting, together with improvements in clinical study design.

Original publication




Journal article


Breast Cancer Res

Publication Date





96 - 99


Breast Neoplasms, Clinical Trials as Topic, Endpoint Determination, Female, Gene Expression Profiling, Genetic Markers, Humans, Oligonucleotide Array Sequence Analysis, Prognosis, Research Design, Treatment Outcome